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Managing Neuropathic Pain in Dogs
Sarah A. Moore*
Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, USA
Disorders of the somatosensory system such as neuropathic pain are common in people 
with chronic neurologic and musculoskeletal diseases, yet these conditions remain an 
underappreciated morbidity in veterinary patients. This is likely because assessment 
of neuropathic pain in people relies heavily on self-reporting, something our veterinary 
patients are not able to do. The development of neuropathic pain is a complex phenom-
enon, and concepts related to it are frequently not addressed in the standard veterinary 
medical curriculum such that veterinarians may not recognize this as a potential problem 
in patients. The goals of this review are to discuss basic concepts in the pathophysiology 
of neuropathic pain, provide definitions for common clinical terms used in association 
with the condition, and discuss pharmacological treatment options for dogs with neu-
ropathic pain. The development of neuropathic pain involves key mechanisms such as 
ectopic afferent nerve activity, peripheral sensitization, central sensitization, impaired 
inhibitory modulation, and pathologic activation of microglia. Treatments aimed at reduc-
ing neuropathic pain are targeted at one or more of these mechanisms. Several drugs 
are commonly used in the veterinary clinical setting to treat neuropathic pain. These 
include gabapentin, pregabalin, amantadine, and amitriptyline. Proposed mechanisms 
of action for each drug, and known pharmacokinetic profiles in dogs are discussed. 
Strong evidence exists in the human literature for the utility of most of these treatments, 
but clinical veterinary-specific literature is currently limited. Future studies should focus 
on objective methods to document neuropathic pain and monitor response to therapy 
in veterinary patients.
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iNTRODUCTiON
Disorders of the somatosensory system such as neuropathic pain affect up to 8% of the general 
population and up to 90% of people living with chronic spinal cord injury (SCI), yet these condi-
tions remain an underappreciated morbidity in veterinary patients (1, 2). Additionally, veterinarians 
have historically received limited background in the concepts of neuropathic pain during training, 
making it more difficult to recognize this potential problem in patients. The goal of this review is to 
summarize basic concepts in the literature related to somatosensory disturbance and neuropathic 
pain and to review recent publications related to the diagnosis and management of neuropathic pain 
in dogs. Terminology related to neuropathic pain is vast, and often misused in both the human and 
veterinary clinical literature. Definitions of important terms relevant to the discussion of neuropathic 
pain, as recommended by the International Association for the Study of Pain (IASP), are summarized 
in Table 1 (3).
TABLe 1 | Summary of terms and definitions relevant to the discussion of neuropathic pain in veterinary patients.
Term Definition
Interoceptive stimulus A sensory stimulus that originates from within the body
Exteroceptive stimulus A sensory stimulus that originates from outside of the body
Pain An unpleasant sensory and emotional experience provoked by a damaging or potentially damaging stimulus
Nociceptive pain Pain caused by a noxious stimulus that is processed by a normally functioning somatosensory system
Neuropathic pain Pain caused by a disease or lesion causing dysfunction of the somatosensory system
Mixed pain Condition of coexisting nociceptive and neuropathic pain
Allodynia Pain provoked by a stimulus that does not normally cause pain
Hyperesthesia Increased sensitivity to stimulation
Paresthesia An abnormal sensation (burning, tingling, “skin crawling”) that can be either spontaneous or provoked
Hyperpathia An abnormally painful reaction to a stimulus
Hypoalgesia Diminished pain in response to a stimulus that would normally be painful
Analgesia Absence of pain in response to a stimulus that would normally be painful
Central sensitization Response of nociceptive neurons within the central nervous system to normally non-painful or sub-threshold sensory stimulus
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THe SOMATOSeNSORY SYSTeM: AN 
OveRview
The somatosensory system serves three major functions. It allows 
perception and reaction to sensory stimuli originating inside the 
body (interoceptive), responds to stimuli originating outside 
the body (exteroceptive), and mediates proprioceptive function 
(4). The first order neurons in pathways of the somatosensory 
system reside in the dorsal root ganglia (DRG), cranial sensory 
ganglia, or the brainstem. The anatomy of DRG neurons has 
been described as pseudounipolar, meaning that they possess 
a single-branched axon, which extends both into the periphery 
to associate with sensory receptors and into the spinal cord to 
form synapses with second-order neurons in either the dorsal 
gray matter or brainstem nuclei (4). The general somatic afferent 
system (GSA) is commonly referred to as the “pain, temperature, 
touch” system, which is partially a misnomer because pain is 
not actually a sensory modality but rather a feeling provoked in 
response to a sensory stimulus. This is the system that transmits 
information related to thermal, mechanical, and chemical stimuli 
from peripheral receptors to the somatosensory cortex (5). The 
general proprioceptive (GP) system is responsible for detecting 
the movement and position of muscles and joints, encompassing 
both conscious and unconscious proprioceptive components (5).
PAiN AND THe GeNeRAL SOMATiC 
AFFeReNT SYSTeM
Pain is classically defined as “an unpleasant feeling provoked 
by intense or damaging stimuli” (6). The generation of pain in 
response to tissue injury involves four basic processes: transduc-
tion, transmission, modulation, and perception. Transduction 
involves the conversion of a noxious stimulus to a nociceptive 
signal at the level of the nociceptor. Transmission is the process by 
which nociceptive signals are propagated along nerve fibers from 
the site of original injury to the CNS. Modulation is the mechanism 
by which nociceptive signals are altered within the CNS through 
either facilitation or inhibition. Perception is the last and most 
important part of the “experience” of pain, involving integration 
of cognitive and emotional responses to the noxious stimulus (7).
In general, pain can be categorized as either nociceptive or 
neuropathic. Nociceptive pain is caused by noxious stimuli which 
are processed by an otherwise normally functioning somatosen-
sory system – for example pain associated with the production 
of pro-inflammatory mediators after a broken bone. Nociceptive 
pain is evolutionarily advantageous by allowing an animal to 
detect and respond to a potentially damaging stimulus. It can be 
further classified as somatic (originating from skin, muscles, and 
joints) or visceral (originating from visceral organs). Neuropathic 
pain is defined as pain caused by a disease or lesion, which leads 
to damage or dysfunction of the somatosensory system (8). The 
term mixed pain refers to the condition of coexisting nociceptive 
and neuropathic pain. It is likely that neuropathic and mixed 
pain are both common but under-recognized phenomena in our 
veterinary patients with long-standing neurologic, orthopedic, or 
other diseases.
Neuropathic pain is a maladaptive phenomenon caused by 
pathologic neuroplasticity, and can become a disease of the neu-
rologic system in its own right by persisting beyond resolution 
of an inciting cause (9). It is caused by a broad range of condi-
tions affecting any organ or tissue that possesses nerve endings. 
Specifically, conditions such as peripheral neuropathy, spinal 
cord disease, chronic musculoskeletal conditions, and brain 
lesions are commonly reported (1, 2, 10–13). Manifestations of 
neuropathic pain include both evoked pain (stimulus depend-
ent hypersensitivity) and spontaneous pain. These signs may be 
either continuous or intermittent in nature. Stimulus-evoked 
hypersensitivity is often categorized further in the literature in 
to the two most common types of neuropathic pain recognized 
and discussed in the clinical setting: allodynia or hyperesthesia 
(14). The term Allodynia originates from the Greek words for 
other (allo) and pain (odynia), and refers to a condition where 
a stimulus not typically considered painful and not encoded 
by nociceptors is perceived to be painful by an individual with 
somatosensory dysfunction. Hyperesthesia refers to a condition 
of increased sensitivity to a stimulus. The term Hyperpathia 
originates from the Greek meaning “increased suffering” and 
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denotes an exaggerated level of pain in response to a stimulus. 
Allodynia and hyperesthesia can both be present in conjunction 
with hyperpathia, and the terms are frequently confused and used 
incorrectly in both the veterinary and human medical literature.
NeUROPATHiC PAiN MeCHANiSMS
The first step in the establishment of neuropathic pain is develop-
ment of a lesion somewhere within the somatosensory system. 
The initiating stimulus is typically associated with nociceptive 
pain. Under normal circumstances, noxious stimuli diminish as 
healing occurs, and the experience of nociceptive pain decreases 
over time. However, intense chronic nociceptive pain can activate 
mechanisms in both the peripheral and central nervous system 
(CNS) that lead to the development of a neuropathic pain state. 
The question of exactly when acute nociceptive pain becomes 
chronic and deleterious is difficult to answer, although an under-
standing of the window during which permanent changes to the 
somatosensory system occur could facilitate better prevention 
and management of neuropathic pain (15).
The key mechanisms which underlie the development of neu-
ropathic pain conditions include the following: ectopic activity 
in afferent nerves, peripheral sensitization, central sensitization, 
impaired inhibitory modulation, and pathologic activation of 
microglia. These mechanisms can occur across as spectrum of 
pathologic processes. Additionally, within a single patient, multi-
ple neuropathic pain mechanisms may be present, and different 
mechanisms can lead to the same clinical signs. Importantly, in 
people, efficacy of a particular drug to treat neuropathic pain 
is not generally dependent on the underlying cause but rather 
the type of neuropathic pain syndrome displayed (16). This 
highlights the complexity of neuropathic pain development and 
maintenance and underscores the need to consider treatment 
plans for each patient on an individual basis (14, 17). Mechanisms 
that underlie the development of neuropathic pain are discussed 
in detail below.
ectopic Afferent Nerve Activity
Ectopic afferent activity refers to injury-induced hyperexcit-
ability, which generates aberrant action potentials in primary 
afferent neurons or in other sites along the nociceptive pathway 
(2). People with ectopic afferent activity report the sensation of 
ongoing spontaneous pain, or paroxysmal shooting pain in the 
absence of an external stimulus (14). Ectopic afferent activity may 
originate from damaged nerve fibers or uninjured adjacent fibers, 
which become activated as a result of non-synaptic signal trans-
mission (7, 9). This ectopic activity is caused by sub-threshold 
oscillations in resting membrane potential, which result in bursts 
of rhythmic nerve depolarization in the absence of an appropri-
ate stimulus. Inflammatory processes ensue, leading to a state of 
peripheral sensitization.
Peripheral Sensitization
Peripheral sensitization is characterized by a reduced threshold 
and increased intrinsic excitability of peripheral nociceptor 
terminals. In most cases, peripheral sensitization will resolve 
as healing occurs. However, it may persist in scenarios of con-
tinued disease or injury, leading to physical alterations in the 
functions of primary afferent neurons (18). Sodium channels 
are considered the primary player in this phenomenon, where 
increased numbers of heterotopic sodium channels such as 
Nav1.8, Nav1.7, and Nav1.3 lower stimulus threshold and result 
in neuropathic pain (19–22).
Central Sensitization
Central sensitization refers a phenomenon by which nociceptive 
input is amplified within the CNS in patients with neuropathic 
pain. Central sensitization occurs when dorsal horn synaptic 
plasticity results in persistent abnormal nociceptive processing. 
After injury, repeated discharges from GSA neurons leads to the 
release of excitatory molecules within the dorsal horn of the spi-
nal cord. This causes postsynaptic effects on second-order noci-
ceptive neurons such as increased expression of voltage-gaited 
sodium channels and alterations in AMPA and NMDA receptors 
(23, 24). These changes enable low-threshold mechanosensitive 
fibers to aberrantly activate second-order nociceptive neurons. A 
potential consequence is that normally innocuous tactile stimuli 
such as light touch can cause pain.
Pathologic Activation of Microglia
Neuroinflammatory mechanisms, including microglial activa-
tion, are also implicated in the induction and maintenance of a 
chronic neuropathic pain state (25). As a result of injury, micro-
glia within the CNS become pathologically activated and respond 
by releasing inflammatory mediators such as ATP and CCL2 (6). 
These, in turn, lead to activation of astrocytes and enhanced 
production of other inflammatory mediators such as TNF, IL-1β, 
and IL-6. These pro-inflammatory cytokines have been shown to 
play a vital role in sensitization in rodent models of neuropathic 
pain by inducing changes in central modulation of painful stimuli 
and hyperexcitability of nociceptive neurons (26, 27).
evALUATiON OF NeUROPATHiC PAiN iN 
THe veTeRiNARY SeTTiNG
Chronic somatosensory dysfunction, primarily in the form of 
neuropathic pain, is common in people living with chronic SCI 
and other diseases (1, 2). Neuropathic pain is also a well-described 
phenomenon in rodent models of traumatic brain injury and 
stroke, in chronic musculoskeletal disease, neuropathy, and 
other illnesses (10–13). In rodents, the presence of neuropathic 
pain can be assessed using objective laboratory techniques such 
as quantitative sensory testing (QST), which are discussed in 
greater detail below. The presence of neuropathic pain in vet-
erinary patients with similar conditions has been explored only 
in a limited fashion. This is likely because neuropathic pain in 
people is typically assessed using bedside examination, where 
patients self-report their pain (14). Dogs, of course, are unable 
to self-report. Additionally, until recently, QST techniques have 
been viewed more as laboratory tools instead of clinical assess-
ments. As such, they have not been employed commonly in the 
veterinary clinical setting.
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History Taking and the Clinical 
examination
Veterinary patients with neuropathic pain may display certain 
clinical signs either visible on clinical examination or reported by 
owners during history taking. Pet owners may not realize their pet 
is displaying signs of pain, so veterinarians should question care-
fully for potential signs in patients at risk. Obvious manifestations 
may include altered reaction to touch, vocalization in the absence 
of an overt painful stimulus, phantom scratching, excessive licking 
or self-mutilation, and persistent lameness/diminished weight-
bearing on a limb. More subtle signs may include decreased 
general activity level, reluctance to climbing or descending stairs, 
diminished jumping behavior, difficulty rising from a seating 
position, trouble getting into and out of the car, changes in body 
posture, and altered demeanor or appetite (28, 29).
Quantitative Sensory Testing
“Sensory testing” in dogs has been historically limited to the 
context of severe SCI, with results inferring prognosis for neu-
rologic recovery (30). This testing involves subjective evaluation 
of the presence or absence of a behavioral response to a strong 
nociceptive stimulus such as pinching the toes – interpreted as 
the “presence” or “absence” of intact nociceptive pathways. At 
best, response can be evaluated as normal, diminished, or absent. 
While an important clinical prognostic indicator in SCI, this 
subjective evaluation provides no ability to assess the presence of 
neuropathic pain, or objectively quantify its severity.
Objective methods to evaluate abnormalities in sensory func-
tion, such as QST, have been developed for use in rodent models 
of SCI and more recently in the human clinical setting (31–33). 
These techniques are useful in diagnosing neuropathic pain and 
in assessing response to treatment interventions aimed its severity. 
Methods of QST produce an objective value called sensory thresh-
old (ST) for an array of stimuli such as pin-prick, light touch, 
vibration, and temperature. In patients with diseases that produce 
diminished sensation, ST will be higher than normal (hypoalge-
sia). In patients with diseases that produce neuropathic pain, ST 
will be lower than normal (hyperesthesia). QST is an important 
part of outcome assessment in translational laboratory animal 
models of acute and chronic pain; however, these techniques have 
not routinely been used in the veterinary clinical setting.
Techniques for QST can also be valuable in assessing dogs 
with various medical conditions (34–36). Procedures for the use 
of devices for mechanical QST using, such as the electronic von 
Frey anesthesiometer (VFA), have been weight-bearing in client-
owned dogs (34–39). Mechanical QST provides an objective eval-
uation of the amount of mechanical pressure that must be applied 
to the patient (in dogs, typically the dorsal surface of the paw with 
the patient positioned in lateral recumbancy) to produce a behav-
ioral response indicating conscious perception of the stimulus. 
The pressure necessary to produce this response is recorded as 
the “ST” for the patient. Using this technique, hyperesthesia is 
manifest as a reduced ST. These techniques have potential utility 
in diagnosing neuropathic pain in dogs, and monitoring response 
to therapies; however, they may be influenced by the technique of 
the investigator and the emotional state of the patient, indicating 
that further work is needed to refine this technique before it can 
be adopted for routine clinical use (39). In rodent laboratory 
studies using similar techniques, a “gentling period” of several 
days is typically suggested to allow the animal to acclimate to the 
testing device and environment prior to initiating testing (33). 
This recommendation stems from the knowledge that anxiety can 
affect the character of behavioral responses observed during QST. 
Obviously, in veterinary patients with spontaneously occurring 
diseases this approach is not feasible. For dogs, a 10–15-min 
acclimation period to the testing room has been suggested in 
conjunction with maintaining a quiet comfortable space with 
limited traffic and distractions (34). Testing using the VFA tech-
nique involves assessing ST in each limb via five stimuli applied 
at least 1 min apart to prevent ST decay between tests (35). Thus, 
the technique requires approximately 30 min per dog per testing 
session to accomplish if all four limbs are evaluated.
Williams et  al. have also recently reported the feasibility of 
thermal QST in normal dogs and those with pain associated with 
osteoarthritis (40). This technique assesses thermal threshold 
latency (TTL) of the ventral surface of the paw with the dog in 
a standing position. The limb is positioned on a glass plate and 
a light source applied below the glass centered on the pad of the 
third digit. The stimulus is applied for a maximum of 30 s and 
terminated automatically when the dog lifts its foot or moves 
off the glass plate. The time between stimulus application and 
automatic termination of the stimulus is recorded as the TTL.
MANAGiNG NeUROPATHiC PAiN
The first, and perhaps most important step, in the management of 
neuropathic pain is identification and treatment (whenever possi-
ble) of the underlying disease affecting the somatosensory system. 
There are many conditions common in veterinary patients, which 
are likely to result in neuropathic pain based on what we know 
from analogous human conditions. Examples include Chiari-like 
malformation/syringomyelia (CM/SM), radiculopathy caused by 
chronic cervical or lumbosacral disc disease, diabetic or other 
polyneuropathy, SCI caused by intervertebral disc extrusion, 
chronic osteoarthritis, and stroke (1, 2, 10–13).
Many of the conditions associated with neuropathic pain may 
also have a clinical component of nociceptive pain. Strategies for 
managing nociceptive pain have been reviewed extensively in the 
recent veterinary literature and will not be discussed here (41, 
42). Management of neuropathic pain in the veterinary setting 
presents challenges, as apparent in CM/SM, where the clinical 
manifestations of neuropathic pain may be refractory to treatment 
and often progress over time (43, 44). Treatments can be targeted 
at any or all of the five mechanisms underlying neuropathic pain, 
which were described above. A recent meta-analysis of the human 
neuropathic pain literature makes strong recommendations for 
the use of drugs such as gabapentin, pregabalin, and tricyclic 
antidepressants (TCA), while weaker recommendations are 
made for tramadol and strong opioids such as morphine (related 
to both efficacy and side effects) and topical lidocaine or capsaicin 
(45). The most common drugs used specifically for neuropathic 
pain the veterinary setting are gabapentin and pregabalin, with 
TCA occasionally referenced (46, 47). A summary of dosing 
TABLe 2 | Common medications used for the management of 
neuropathic pain in dogs.
Drug Dosage (mg/kg) Frequency (h) Reference
Gabapentin 10–20 Q8 (48, 49)
Pregabalin 4 Q12 (50)
Amitriptyline 3–4 Q12 (51)
Amantadine 3–5 Q12–24 (42, 52)
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recommendations for medications used to manage neuropathic 
pain in dogs can be found in Table 2.
Gabapentin
Gabapentin was originally marketed as an anticonvulsant medica-
tion but was subsequently found to have beneficially effects in the 
management of neuropathic pain (53, 54). It is currently approved 
by the FDA for use in postherpes neuralgia. The extended release 
formulation, gabapentin enacarbil, is approved for use in restless 
leg syndrome (RLS) (42). Gabapentin is a structural analog of 
GABA. It appears to decrease central sensitization by inhibiting 
presynaptic calcium channels in the dorsal horn (55). Gabapentin 
may also have efficacy related to sodium channel blockade and 
elimination of ectopic nerve activity (55).
The current evidence for gabapentin as an analgesic medica-
tion in dogs is low; however, it is commonly used in the clinical 
setting. Several studies have examined the efficacy of gabapentin 
as an adjunctive analgesic after surgical procedures such as fore-
limb amputation, mastectomy, and hemilaminectomy (56–58). 
Wagner et al. (56) found no difference between gabapentin and 
placebo to reduce the need for postoperative opioids when dosed 
at 10 mg/kg Q12 h in patients undergoing forelimb amputation. 
Aghighi et al. (57) found no difference in gabapentin compared 
to placebo in management of postoperative pain after interverte-
bral disc extrusion. Crociolli et al. (58) found that perioperative 
administration of gabapentin at 10 mg/kg immediately prior to 
surgery and Q12 h for 3 days following mastectomy significantly 
decreased postoperative opioid requirements. The fact that all 
three studies used a dosing frequency of Q12 h may explain the 
mixed results, as previous pharmacokinetic studies have sug-
gested appropriate dosing is 10–20 mg/kg every 8 h in dogs (48, 
49). Additionally, gabapentin was evaluated acutely after injury in 
all three studies. Because neuropathic pain is a chronic phenom-
enon, it is likely that gabapentin’s efficacy to manage nociceptive 
pain was the only thing truly being evaluated. Several case series 
discuss the role of gabapentin in the management of chronic neu-
ropathic pain associated with CM/SM, but there are no controlled 
studies in the veterinary literature (59–61). Additionally, a recent 
study compared gabapentin to topiramate as an add-on to car-
profen in the management of CM/SM (59). This study reported 
no improvement in pain scores assigned via visual analog scale; 
however, improvement in quality of life scores for dogs receiving 
gabapentin was observed. While it is likely that gabapentin has 
efficacy against neuropathic pain based on the human literature 
and on anecdotal evidence, controlled studies will be required to 
understand the role of gabapentin to manage neuropathic pain in 
veterinary patients.
Pregabalin
Pregabalin is structurally similar to gabapentin but has higher 
oral bioavailability and a longer half-life (42, 50). In a single-dose 
pharmacokinetic study performed in normal dogs, a dose of 4 mg/
kg produced plasma drug concentrations within the predicted 
therapeutic range extrapolated from the human literature (50). 
Elimination half-life of the drug in that study supported Q12-h 
dosing. There are no controlled studies evaluating the efficacy 
of pregabalin to treat neuropathic pain in veterinary patients, 
although a case series of dogs with CM/SM reports its use (47). 
The current cost of pregabalin often prevents its use as a first line 
drug for veterinary patients.
Tricyclic Antidepressants
The effects of neuromodulatory drugs such as TCA in managing 
neuropathic pain are distinct from their antidepressant effects 
(62). TCAs including amitriptyline are considered a first-line 
therapy for neuropathic pain in humans, with demonstrated 
efficacy in diseases such as postherpetic neuralgia, poststroke 
pain, and chronic low back pain (63). TCAs exert analgesic effects 
in several ways, including inhibiting reuptake of serotonin and 
norepinephrine, antagonism of voltage-gaited sodium chan-
nels, and antagonism of NMDA receptors. There are no clinical 
trials, or experimental studies evaluating the use of TCAs for 
neuropathic pain in dogs, but a case for their utility can be made 
based on the human literature. A small case series describes the 
management of neuropathic pain in three dogs with mixed results 
using amitryptiline alone or in conjunction with other analgesics 
(46). A recent pharmacokinetic study of amitryptiline in dogs 
suggests that dosing at 3–4 mg/kg every 12 h will reach target 
drug concentrations extrapolated from people (51).
Amantadine
Amantadine is an NDMA antagonist that has shown mixed 
results in the treatment of neuropathic pain in humans (64). 
Amantadine may decrease central sensitization, decreases opioid 
tolerance in some patients, and is suggested to enhance the effects 
of NSAIDS, gabapentin, and opioids (65). Dosing at 3–5 mg/kg 
Q24 h is typically suggested throughout the veterinary literature, 
although a recent pharmacokinetic study of single-dose amanta-
dine in greyhounds suggests that Q12-h dosing might be more 
rational (42, 52, 65, 66). A single case report describes the use 
of amantadine specifically for neuropathic pain in a dog, and no 
studies evaluating the analgesic effects of amantadine specifically 
to treat neuropathic pain are available in dogs (67). However, a 
randomized, placebo-controlled trial evaluated the use of aman-
tadine in conjunction with meloxicam in dogs with osteoarthritis 
and showed significant improvement in pain scores for dogs 
receiving amantadine compared to placebo (65).
Opioids
The role of opioids in the management of people with neuropathic 
pain is both controversial and complex. A recent meta-analysis 
found moderate evidence for their use to decrease the intensity 
of neuropathic pain with intermediate-term treatment, but also 
cited significant bias in currently available studies, and the need 
February 2016 | Volume 3 | Article 126
Moore Neuropathic Pain in Dogs
Frontiers in Veterinary Science | www.frontiersin.org
for prospective studies focusing on adverse effects (68). Recent 
studies also indicate that the use of opioids in some patients may 
contribute to a condition called opioid-induced hyperalgesia 
(69). Opioid-induced hyperalgesia is characterized by a height-
ened state of pain sensation characterized by both a lowered pain 
threshold and a decrease in tolerance for pain (70). Patients with 
opioid-induced hyperalgesia report increases in sensitivity to pain 
and higher pain scores as opioid doses are increased. The exact 
mechanism by which this occurs is not completely understood, 
but opioid effects on NMDA and μ receptors are likely involved 
(71). In the context of postoperative pain, extensive use of opioids 
prior to a procedure has been associated with a more painful and 
prolonged recovery (72). Drugs considered strong opioid agonists, 
such as oxycodone and morphine, show moderate efficacy in the 
management of neuropathic pain but have significant side effects 
such as constipation of other gastrointestinal disturbances with 
long-term use. Tramadol is considered a weak opioid agonist, 
but may also exert effects similar to TCAs by inhibiting reuptake 
of serotonin and noradrenaline to aid in the management of 
neuropathic pain (73).
Cannabinoids
Of recent interest in the management of neuropathic pain are the 
cannabanoids. Cannabinoids are a family of chemicals derived 
from the cannabis (marijuana) plant. Many pharmacologically 
active cannabinoids have been identified but the two with the 
strongest evidence for analgesic effects are tetrahydrocannabinol 
(THC), which also has psychoactive effects, and cannabidiol 
(CBD). Cannabinoids exert their effects within the body via two 
well-studied receptors: CB1 and CB2. CB1 receptors are present 
in high numbers in the brain and spinal cord, as well as visceral 
organs and adipose tissue. Activation of CB1 receptors leads to 
inhibited release of acetylcholine, dopamine, and glutamate. CB1 
also modulates opioid, NMDA, and GABA receptors (74, 75). 
Most known adverse effects associated with cannabinoids are 
associated with central CB1 receptor effects (76). CB2 receptors 
are found in the highest concentrations on hematopoietic and 
immune cells, including microglial cells (75, 76). In normal 
health, CB2 receptors are expressed only at low levels in the CNS 
but are rapidly upregulated in both neurons and microglia after 
injury or inflammation (76). Several peripherally restricted CB1 
or CB2 receptor agonists have been developed to circumvent the 
centrally meditated side effects of cannabinoids. These drugs 
have been evaluated for the treatment of inflammation and 
neuropathic pain. Studies have shown mixed results, a summary 
of which can be found in a recent review of the human literature 
regarding cannabinoids in pain management (76). Additionally, 
a recent meta-analysis made weak recommendations against the 
use of cannabinoids for management of neuropathic pain (45). 
While medical marijuana or cannabis-based products have not 
historically been a topic for discussion in veterinary medicine, 
the use of cannabinoids deserves mention here for two reasons. 
First, future studies may support the use of novel restricted CB1 
or CB2 receptor agonists in veterinary patients. Additionally, 
a commercially available hemp-based supplement has been 
recently marketed for use in dogs and is available online without 
a prescription (Canna-Pet®). This product has not been evaluated 
by the FDA for cannabinoid content, or efficacy. No quantitative 
information regarding CBD or other cannabinoid content is 
listed on the website for this product. Additionally, the company 
declined to provide quantitative information on CBD content 
of their products when requested by the author specifically for 
inclusion in this review.
NON-PHARMACOLOGiC MANAGeMeNT
Several non-pharmacologic techniques for managing neuro-
pathic pain are suggested throughout the veterinary literature. 
Examples include acupuncture, medical massage, cold or heat 
therapy, shock wave therapy, platelet-rich plasma, and dietary 
supplements (29). While veterinary-specific literature is limited 
with respect to each of these modalities in the management of 
neuropathic pain, a recent review article summarizes the con-
cepts behind utility of these techniques for pain management in 
dogs and cats (77).
SUMMARY
Neuropathic pain is likely an under-recognized condition in 
veterinary patients with an assortment of neuromusculoskeletal 
diseases. Specific literature related to diagnosis and treatment 
of neuropathic pain in dogs is limited, although information 
related to mechanisms and treatment options can be extrapolated 
from the human literature. Drugs specifically targeted at reduc-
ing neuropathic pain, such as gabapentin and pregabalin, will 
require controlled prospective studies evaluating their efficacy 
to reduce clinical signs compatible with neuropathic pain such 
as hyperesthesia and allodynia. Veterinary clinicians should be 
aware of neuropathic pain as a potential entity in patients and 
should consider it when developing a multimodal approach to 
pain management.
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